Drug intelligence / Profile preview

BT-173

Development stage: Unknown
Lead developer: Rila Therapeutics

Overview

BT-173 is a predecessor compound that served as the foundational molecule for RLA-23174, Rila Therapeutics' lead drug. Its development and optimization into RLA-23174 involved preclinical collaborations with ShangPharma Innovation and the medicinal chemistry team at ChemPartner. This foundational work was a key factor in the establishment of Rila Therapeutics in 2021.

Targets

HIPK2 (Homeodomain-interacting protein kinase 2)

Beyond the preview

Go deeper on BT-173.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT-173.

Explore the full profile